- Sleep apnea devices market growth also driven by the current pandemic which has made it exponentially more difficult for patients to seek treatment for their condition
- Registered with the FDA as a Specification Developer, Vivos develops and markets the first non-surgical, non-invasive and cost-effective solution for the estimated billion of people globally who suffer from OSA
- Vivos believes its proprietary system is poised to provide the most significant breakthrough in OSA treatment since CPAP
The global sleep apnea market is expanding rapidly, being expected to reach $13.24 billion by 2027, from $7.81 billion in 2019, exhibiting a CAGR of 6.8 percent. In a report titled “Sleep Apnea Devices Market Size . . .”, Fortune Business Insights notes that the rising cases of cardiovascular disorders and diabetes among the geriatric population are some of the primary causes of the surge in sleep apnea (http://ibn.fm/wlVz2). Additionally, a reduction in polysomnography, laboratory-based CPAP (Continuous Positive Airway Pressure) and bi-level therapy can cause a decline in diagnosis of new sleep apnea cases as well as exert a negative impact on the growth of the market. Moreover, the report cites NCBI data indicating a 50 percent decline in compliance rates for CPAP devices. This has created the need for alternative oral appliances to provide comfort to sleep apnea patients.
An emerging global leader in the treatment of obstructive sleep apnea (“OSA”), Vivos Therapeutics, Inc. is uniquely positioned to capitalize on this growing market and the increased demand for sleep apnea alternative solutions. The company’s proprietary Vivos System(R) is the first treatment modality for mild to moderate OSA in adults that does away with the need for lifelong interventions. The system’s treatment time is a fraction of that of its alternatives, potentially offering patients lasting relief in a matter of months, eliminating the need for surgery (http://ibn.fm/xdHWd).
The leading cause of OSA is a deficiency in the development of craniofacial anatomy. Pneumopedics is the natural process introduced by Vivos biomimetic technology where the airway tissues are remodeled resulting in enhanced capacity over the course of treatment, which typically ranges from 18 to 24 months. Unlike many other approaches, it aims for a lasting resolution by targeting the root cause of sleep apnea.
Registered with the FDA as a Specification Developer, Vivos develops and markets a number of oral appliances. Its technology represents the first non-surgical, non-invasive and cost-effective solution for the estimated one billion people worldwide who suffer from OSA. Vivos Therapeutics believes its technology represents the most important breakthrough in OSA treatment since CPAP, which involves the use of special face or nasal masks.
The company’s oral appliances have proven to be effective in more than 15,000 patients successfully treated worldwide by approximately 1,350 trained dentists. Vivos’ vision is to provide clinicians with the tools to provide the best alternative solution to treat OSA.
For more information, visit the company’s website at www.VivosLife.com.
NOTE TO INVESTORS: The latest news and updates relating to Vivos Therapeutics are available in the company’s newsroom at http://ibn.fm/VVOS
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.